GlassScriptPhysician profile
Ambar M Patel
NPI 1366649758
$4,350.41
in general payments reported to CMS, 2019-2025
24 companies · $476 in 2025
The $476 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $974 · 2020: $39.88 · 2021: $1,483 · 2022: $896 · 2023: $246 · 2024: $235 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $957.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,252.62 | 2019-2025 | Cardiomems, Amplatzer Amulet, Optis |
| Edwards Lifesciences Corporation | $928.49 | 2019-2021 | |
| Boston Scientific Corporation | $592.92 | 2019-2024 | Watchman Access System |
| Novartis Pharmaceuticals Corporation | $198.55 | 2019-2022 | |
| Shockwave Medical, INC | $179.96 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amgen INC. | $167.50 | 2019-2025 | Repatha |
| Heartflow, INC. | $144.27 | 2022 | |
| Cvrx, INC. | $133.83 | 2025 | Barostim Neo System |
| Abiomed | $128.95 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $125.05 | 2019 | |
| Akcea Therapeutics, INC. | $109.54 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $64.32 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.95 | 2019 | |
| Sanofi-Aventis U.S. LLC | $52.38 | 2019 | |
| Gilead Sciences, INC. | $44.95 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $39.48 | 2019 | |
| Recor Medical INC | $24.93 | 2024 | Paradise Renal Denervation System |
| E.R. Squibb & Sons, L.L.C. | $23.44 | 2022 | |
| Medtronic, INC. | $22.35 | 2021 | |
| Elutia, INC. | $20.16 | 2019 | |
| Novo Nordisk INC | $14.75 | 2020 | |
| Medtronic Vascular, INC. | $13.43 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.59 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ambar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.